MYC and B-cell non-Hodgkin lymphoma: Promising preliminary results have been reported for a phase II study (NCT01092182) of DA-EPOCH-R in MYC-rearranged aggressive B-cell lymphomas, which showed that the PFS, TTP, and OS were 79%, 86%, and 77%, respectively, at a median follow-up of 14 months51.